<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Padma R</submitter><funding>University of Dayton</funding><funding>NEI NIH HHS</funding><funding>Knights Templar Eye Foundation</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><pagination>dev204373</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12338917</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>152(14)</volume><pubmed_abstract>During development, regulation of gene expression is key to cellular homeostasis. Gene expression regulation by non-coding RNAs involves the prevention of mRNA accumulation or the inhibition of translation of their target gene. In a forward-genetic screen to identify the microRNA involved in the growth and patterning of the Drosophila eye, we identified the highly conserved miR-137. Gain of function of miR-137 results in a reduced-eye phenotype by downregulating retinal determination and differentiation markers, and by upregulating negative regulators of eye development, such as Wingless (Wg) and Homothorax (Hth). Loss of function of miR-137 results in an enlarged-eye phenotype. Using bioinformatics and genetic approaches, we identified the oncogene Myc as the target of miR-137. Gain of function of Myc can rescue the reduced-eye phenotype of miR-137 gain of function, and vice versa. We tested the role of miR-137 in regulating Myc levels in the RasV12;scribRNAi, a tumor model of oncogenic cooperation that results in neoplastic tumors. Gain of function of miR-137 in the RasV12;scribRNAi background significantly reduced tumor phenotype as well as Myc levels in the eye. Our studies highlight miR-137 as a post-transcriptional regulator of Myc and a promising therapeutic target for diseases associated with Myc accumulation.</pubmed_abstract><journal>Development (Cambridge, England)</journal><pubmed_title>miR-137 targets Myc to regulate growth during eye development.</pubmed_title><pmcid>PMC12338917</pmcid><funding_grant_id>R01 EY032959</funding_grant_id><funding_grant_id>1RO1EY032959-01</funding_grant_id><funding_grant_id>KTEF-411281</funding_grant_id><funding_grant_id>2024-29</funding_grant_id><pubmed_authors>Yogi S</pubmed_authors><pubmed_authors>Sangeeth A</pubmed_authors><pubmed_authors>Padma R</pubmed_authors><pubmed_authors>Subramanian M</pubmed_authors><pubmed_authors>Rai A</pubmed_authors><pubmed_authors>Singh A</pubmed_authors><pubmed_authors>Kango-Singh M</pubmed_authors><pubmed_authors>Chimata AV</pubmed_authors></additional><is_claimable>false</is_claimable><name>miR-137 targets Myc to regulate growth during eye development.</name><description>During development, regulation of gene expression is key to cellular homeostasis. Gene expression regulation by non-coding RNAs involves the prevention of mRNA accumulation or the inhibition of translation of their target gene. In a forward-genetic screen to identify the microRNA involved in the growth and patterning of the Drosophila eye, we identified the highly conserved miR-137. Gain of function of miR-137 results in a reduced-eye phenotype by downregulating retinal determination and differentiation markers, and by upregulating negative regulators of eye development, such as Wingless (Wg) and Homothorax (Hth). Loss of function of miR-137 results in an enlarged-eye phenotype. Using bioinformatics and genetic approaches, we identified the oncogene Myc as the target of miR-137. Gain of function of Myc can rescue the reduced-eye phenotype of miR-137 gain of function, and vice versa. We tested the role of miR-137 in regulating Myc levels in the RasV12;scribRNAi, a tumor model of oncogenic cooperation that results in neoplastic tumors. Gain of function of miR-137 in the RasV12;scribRNAi background significantly reduced tumor phenotype as well as Myc levels in the eye. Our studies highlight miR-137 as a post-transcriptional regulator of Myc and a promising therapeutic target for diseases associated with Myc accumulation.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-05-04T15:24:39.495Z</modification><creation>2026-04-07T20:38:38.039Z</creation></dates><accession>S-EPMC12338917</accession><cross_references><pubmed>40554764</pubmed><doi>10.1242/dev.204373</doi></cross_references></HashMap>